ALLR - Powerful Pop and Pullback follows Phase 2 News

2023-12-05 08:49:20 ET

DENVER, Colo., Dec 5, 2023 ( www.247marketnews.com )- Allarity Therapeutics, Inc. (NASDAQ: ALLR) reported, this morning, hopeful initial results from its ongoing Phase 2 clinical trial evaluating the efficacy of its PARP inhibitor, stenoparib, in women with advanced ovarian cancer. One patient, of the five evaluable patients included in the initial data analysis, experienced a complete response and the other four demonstrated stable disease. All evaluable participants, with prior PARP inhibitor therapy and chemotherapy, showed significant tumor shrinkage.

Allarity is trading at $0.80, up $0.19 (+31.08%), on 10.7 shares traded. Its 52-week range is $0.45 to $1,890.00. This pulled way back its premarket high, but if it can breakthrough the $1 resistance, on strong volume, it doesn’t have much resistance …

The post Powerful Pop and Pullback follows Phase 2 News appeared first on 24/7 Market News .

For further details see: